沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

已收盘 09-24 16:08:31

4.830

-0.170

-3.40%

最高4.995	最低4.805	成交量67.40万
今开4.990	昨收5.000	日振幅3.80%
总市值32.70亿	流通市值32.70亿	总股本6.77亿
成交额326.74万	换手率0.10%	流通股本6.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":4.83,"timestamp":1790237311010,"preClose":5,"halted":0,"volume":674000,"delay":0,"changeRate":-0.03399999999999999,"floatShares":677000000,"shares":677000000,"eps":-0.3568293290250731,"marketStatus":"已收盘","change":-0.17,"latestTime":"09-24 16:08:31","open":4.99,"high":4.995,"low":4.805,"amount":3267430,"amplitude":0.038,"askPrice":4.9,"askSize":8000,"bidPrice":4.83,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-0.24668861744061107,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790299800000},"marketStatusCode":5,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":5,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":1.254654,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996","defaultTab":"news","newsList":[{"id":"2669602624","title":"先健科技(01302)：SureCham™主动脉弓单分支覆膜支架系统进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2669602624","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669602624?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:12","pubTimestamp":1790251926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先健科技 发布公告，于2026年9月24日，本公司收到国家药品监督管理局的正式书面通知，确认由本公司与国家心血管病中心中国医学科学院阜外医院舒畅教授团队联合研发的SureCham主动脉弓单分支覆膜支架系统进入国家药品监督管理局创新医疗器械特别审查程序(该程序)。该产品适用于治疗累及主动派弓部的主动脉夹层，为本公司第十九个进入国家药品监督管理局该程序的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDEV","PTH","BK1583","HART","MEDX","01302","09996","LGHT","BK1600","159883","AGNG","RSPH","GDOC","LNGR","IEIH","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467824","title":"【投融资动态】瑞神安股权转让融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669467824?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:22","pubTimestamp":1790248976,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于9月21日公布的信息整理，常州瑞神安医疗器械有限公司股权转让融资，交易额未披露。常州瑞神安医疗器械有限公司坐落于江苏常州国家级开发区，是专注于植入式医疗器械产品的开发、生产、销售的创新型企业。公司创办人和投资人来自于清华大学专家，风险投资和业内精英。产品源自于与清华大学微电子所的成果转化，并经过产业化团队长期的投入研制而形成。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400035384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1100","BK1583","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461550","title":"迈普医学最新公告：取得口腔可吸收修复膜医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461550","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669461550?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:00","pubTimestamp":1790244023,"startTime":"0","endTime":"0","summary":"迈普医学(301033.SZ)公告称，公司已取得国家药品监督管理局下发的第三类医疗器械注册证，自主研发的“口腔可吸收修复膜”产品首次注册已完成。该产品与骨粉联合使用，适用于口腔牙缺失需种植修复时起物理阻隔作用，是公司向口腔科业务拓展的重要产品，有助于提升公司在再生医学植入医疗器械领域的竞争优势。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1574","BK1583","BK1100","BK0251","09996","301033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669838466","title":"硕世生物(688399.SH)取得两项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669838466","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669838466?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:17","pubTimestamp":1790241437,"startTime":"0","endTime":"0","summary":"智通财经APP讯，硕世生物(688399.SH)发布公告，公司近日收到国家药品监督管理局签发的医疗器械注册证(体外诊断试剂)，产品名称：丙型肝炎病毒核酸检测试剂盒(荧光PCR法)、基孔肯雅病毒核酸检测试剂盒(荧光PCR法)。上述《医疗器械注册证》的取得，丰富了公司产品种类，扩充了公司在体外诊断领域的布局，不断满足多元化的临床需求，将增强公司综合竞争力，有利于进一步提高公司的市场拓展能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","PTH","688399","MEDX","GDOC","LGHT","IEIH","HART","BK1583","AGNG","BK1100","159883","MDEV","RSPH","09996","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669878465","title":"迈克生物(300463.SZ)取得三项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669878465","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669878465?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:50","pubTimestamp":1790239833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈克生物(300463.SZ)发布公告，公司于近日收到四川省药品监督管理局颁发的三项《医疗器械注册证》，分别为总Ⅰ型胶原氨基端延长肽测定试剂盒(直接化学发光法)、β-胶原特殊序列测定试剂盒(直接化学发光法)、骨钙素测定试剂盒(直接化学发光法)。三款产品均系公司直接化学发光平台新试剂产品，主要用于骨质疏松的辅助诊断。截至目前，公司在直接化学发光平台下已累计取得145项试剂类产品注册证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","RSPH","09996","BK1100","LNGR","AGNG","HART","IEIH","MDEV","BK0046","MEDX","LGHT","300463","BK1574","BK0012","159883","PTH","BK1583","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119700392","title":"沛嘉医疗-B 2026年中期财报：营收4.25亿元，同比增长20.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119700392","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119700392?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:53","pubTimestamp":1790153624,"startTime":"0","endTime":"0","summary":"2026年中期，沛嘉医疗-B实现营收4.25亿元，同比增加20.1%，主要受到旗下经导管瓣膜治疗和神经介入业务增长的带动。毛利率为68.3%，较去年同期下降1.8个百分点。公司报告期内销售及分销开支为1.17亿元，同比减少19.4%；行政开支为0.54亿元，同比减少13.6%；研发投入0.88亿元，同比下降23.5%。经营活动所得现金净额约为0.49亿元，同比大幅提升1394.5%。神经介入产品在政策与市场环境的带动下，继续保持增长趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"沛嘉医疗-B 2026年中期财报：营收4.25亿元，同比增长20.1%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669121578","title":"股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司完成医疗器械经营许可证变更登记的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669121578","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669121578?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:26","pubTimestamp":1790101571,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，步长制药报收于14.77元，上涨0.0%，换手率0.39%，成交量4.1万手，成交额6056.51万元。当日关注点交易信息汇总：9月22日主力资金净流出284.82万元，占总成交额4.7%。公司公告汇总：控股子公司上海合璞医疗完成医疗器械经营许可证库房地址变更，新增奉贤区地灵路950号等多处库房，冷链产品仍委托第三方运输贮存。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","603858","BK1574","BK1100","BK0196","BK1583","BK0239","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669084156","title":"中新集团(601512.SH)拟出资不超2000万元参投基金 投向医疗器械和生物技术领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2669084156","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669084156?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:31","pubTimestamp":1789979512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中新集团(601512.SH)发布公告，公司拟作为有限合伙人以自有资金参与投资安徽道彤耀辉股权投资合伙企业(有限合伙)，该基金专注于医疗器械和生物技术领域的股权投资。目标基金本轮拟引进多家投资者，目标总规模不超过11亿元，最终以实际募集情况为准。公司认缴出资不超过2000万元，且占比不超过最终目标基金认缴总额的5%。本次投资符合公司战略发展规划，在获取财务回报的同时，有助于公司优化产业投资布局，从而有效补充园区开发运营业务链条，强化园区开发运营主业，提升公司产业园区开发运营的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","AGNG","09996","RSPH","601512","BK1574","159883","IEIH","HART","PTH","MEDX","BK0273","WDNA","BK1583","BK1100","LGHT","MDEV","LNGR","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669535961","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669535961","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669535961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:03","pubTimestamp":1789974221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规划涵盖创新药、创新医疗器械、人工智能驱动药物发现，以及CDMO/CRO等技术领域，显示政策正对整条价值链作出广泛支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091168.USD","06990","09996","AGNG","IE00B543WZ88.USD","01093","HART","MEDX","RSPH","159992","IEIH","LU0029874061.USD","KURE","LU1242518931.SGD","159883","06978","FTXO","TFNS","BK4566","BK1576","LU0516422366.SGD","LU0516422440.USD","MDEV","LGHT","LU2417539215.USD","PTH","01276","IBBQ","GDOC","LU0359201885.HKD","LU0455707207.USD","IYF","LU1242518857.USD","01801","SG9999002463.SGD","02269","LU1807302812.USD","BK4588","LU1244550494.USD","LU1366192091.USD","LU0029874905.USD","LU0067412154.USD","LU0128525689.USD","LU0456827905.SGD","LU0561508036.HKD","LU3063872942.SGD","LNGR","LU1226287875.USD","03347","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130187","title":"大行评级丨花旗：医药工业发展“十五五”规划利好创新药及医疗器械，首选恒瑞医药及信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130187","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669130187?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:14","pubTimestamp":1789971280,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","BK1161","LU2097828474.EUR","LU0607220059.USD","BK1589","LU2097828631.EUR","HK0000165453.HKD","LU1188198961.HKD","LU2543165471.USD","LU0463099449.HKD","BK1574","LU0326950275.SGD","LU0455707207.USD","BK1583","BK1100","BK1191","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0149534421.HKD","LU0244354667.USD","LU1023057109.AUD","KURE","LU2097828805.USD","01276","06978","LU1831875114.USD","LU2328871848.SGD","LU0359201885.HKD","LU0359202008.SGD","01801","09996","LU2488822045.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668321923","title":"透景生命(300642.SZ)：两款产品取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2668321923","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668321923?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:53","pubTimestamp":1789732433,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)发布公告，公司控股子公司江西透景生命科技有限公司(以下简称“江西透景”)、上海脉示生物技术有限公司(以下简称“脉示生物”)于近日分别取得江西省药品监督管理局、上海市药品监督管理局颁发的医疗器械注册证。涉及产品：“全自动流式荧光发光免疫分析仪(型号、规格:TESMIF5000、 TESMIF5000M)”、“四项抗癫痫药物浓度测定试剂盒(液相色谱串联质谱法)”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","BK1100","LNGR","BK0239","BK1574","159883","AGNG","09996","BK1583","GDOC","PTH","RSPH","300642","MDEV","HART","BK0046","LGHT","IEIH","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668915211","title":"十部门：“十五五”重点发展外骨骼机器人、脑机接口驱动外骨骼、AI步态分析系统等康复医疗器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2668915211","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668915211?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:15","pubTimestamp":1789694113,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["RSPH","PBOT","PTH","QTOC","IEIH","BK1583","GDOC","159883","MEDX","VTHR","MNTL","AGIX","AGNG","IBRN","BK1100","HART","ROBO","KOMP","LGHT","CHAT","LNGR","AIPO","BK1574","09996","MDEV","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667797601","title":"新产业最新公告：获得全自动核酸检测分析系统医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2667797601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667797601?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:34","pubTimestamp":1789551266,"startTime":"0","endTime":"0","summary":"新产业(300832.SZ)公告称，公司收到国家药品监督管理局颁发的1项《医疗器械注册证》，产品为全自动核酸检测分析系统(型号：MolecisionR8)，属Ⅲ类医疗器械，有效期至2031年9月13日。该产品基于实时荧光PCR检测原理，可实现封闭式全流程一体化检测，支持多模块并行运行，具有防污染设置。此次注册证的取得丰富了公司分子诊断产品线，但对近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600027523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","300832","BK1574","BK1100","BK1583","BK0239","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667609173","title":"戴维医疗最新公告：变更医疗器械生产许可证新增监护及呼吸设备生产范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2667609173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667609173?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:04","pubTimestamp":1789549445,"startTime":"0","endTime":"0","summary":"戴维医疗(300314.SZ)公告称，公司因生产经营需要，对生产范围进行变更，在原有基础上增加“第Ⅲ类：07-04-监护设备，08-01-呼吸设备”，并于近日取得浙江省药品监督管理局颁发的变更后《医疗器械生产许可证》。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300314","159883","BK0251","09996","BK1574","BK1583","BK0042","BK0048","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667400546","title":"贝康医疗-B(02170.HK)：GEMS系列玻璃化冷冻液及解冻液套装获国家药监局颁发三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2667400546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667400546?lang=zh_cn&edition=full","pubTime":"2026-09-15 21:46","pubTimestamp":1789479966,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","09996","BK1222","02170","BK1597","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690153","title":"浙商证券：医疗器械子版块多因素交织 低值耗材板块表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667690153?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:06","pubTimestamp":1789437973,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙商证券发布研报称，展望2026年下半年，该行认为医疗器械子版块外部发展环境和内部发展逻辑略有不同，多因素交织。其他子版块净利润受外汇损益等因素较大营运能力：家用医疗板块、IVD、低值耗材板块应收账款周转率均有提升，考虑到存货周转率和资产周转率维持稳定，IVD和低值耗材板块ROE有所提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HART","IEIH","GDOC","LGHT","BK1583","AGNG","09996","RSPH","159883","BK1100","PTH","MEDX","601878","BK1574","MDEV","LNGR","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667766859","title":"佰仁医疗最新公告：主动脉根部扩大补片进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2667766859","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667766859?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:01","pubTimestamp":1789383662,"startTime":"0","endTime":"0","summary":"佰仁医疗(688198.SH)公告称，公司自主研发的主动脉根部扩大补片获国家药监局医疗器械技术审评中心同意，进入创新医疗器械特别审查程序。该产品为国内首个专用于主动脉根部扩大术的补片，旨在解决SAVR患者瓣环过小导致的瓣膜与患者不匹配问题。产品以聚酯精编织物为基质，覆有Ⅰ型胶原蛋白涂层，分为平片型与柱片型两种规格。此次进入创新审查程序有望缩短注册周期，但对近期业绩不会产生重大影响，产品注册上市仍存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400027452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","09996","BK1574","BK1583","BK0251","688198","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667557655","title":"港股异动 | 沛嘉医疗-B(09996.HK)涨超3% GeminiOne®经导管缘对缘修复系统注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667557655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667557655?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:18","pubTimestamp":1789370281,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1583","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863208","title":"“超30家药企长期行贿”，涉案医院回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863208","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667863208?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:36","pubTimestamp":1789356960,"startTime":"0","endTime":"0","summary":"澎湃新闻首席记者 李潇潇9月13日，国家医保局发布《医疗机构涉医药购销商业贿赂案》一文提到，仅2025年下半年，河北医科大学第二医院就涉及9件司法刑事判决。在国家医保局9月13日最新披露的信息中，有超过30家医药企业长期对河北医科大学第二医院工作人员行贿。具体到河北祥恩医疗器械贸易有限公司一家，该公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GDOC","LGHT","AGNG","BK1100","IEIH","09996","MEDX","PTH","RSPH","LNGR","BK1574","BK1583","HART","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667333676","title":"股市必读：康众科技新发布《康众科技关于召开科创板2026年半年度医疗器械及医疗设备行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667333676","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667333676?lang=zh_cn&edition=full","pubTime":"2026-09-14 04:43","pubTimestamp":1789332190,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，康众科技报收于37.51元，下跌4.21%，换手率1.23%，成交量1.09万手，成交额4075.56万元。公司公告汇总：康众科技将于9月17日召开科创板2026年半年度医疗器械及医疗设备行业集体业绩说明会，董事长、财务总监及独立董事将出席并回应投资者提问。投资者可于9月11日至9月16日16:00前通过上证路演中心或公司邮箱提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400002038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09996","BK1100","BK0251","BK1583","159883","688607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":0.0373},{"period":"1month","weight":-0.0602},{"period":"3month","weight":0.2438},{"period":"6month","weight":-0.1843},{"period":"1year","weight":-0.2163},{"period":"ytd","weight":-0.1681}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.053778},{"month":5,"riseRate":0.6,"avgChangeRate":-0.096849},{"month":6,"riseRate":0.571429,"avgChangeRate":0.041819},{"month":7,"riseRate":0.571429,"avgChangeRate":0.044814},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.034075},{"month":9,"riseRate":0.285714,"avgChangeRate":0.008262},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}